Literature DB >> 21156408

Classification of ovarian carcinomas based on pathology and molecular genetics.

Emanuela D'Angelo1, Jaime Prat.   

Abstract

Malignant epithelial tumours (carcinomas) are the most common ovarian cancers and the most lethal gynaecological malignancies. Based on light microscopy and molecular genetics, ovarian carcinomas are subdivided into at least five main subtypes that account for over 95% of cases and are inherently different diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to chemotherapy and outcome. For successful subtype-specific treatment, reproducible pathological diagnosis of tumour cell type is critical. Recent investigations have also demonstrated that a significant number of cancers traditionally thought to be primary ovarian tumours (particularly serous, endometrioid and clear cell carcinomas) originate in the fallopian tube and the endometrium and involve the ovary secondarily. In this review we summarise recent advances in the molecular pathology, which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156408     DOI: 10.1007/s12094-010-0599-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  27 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

Authors:  M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman
Journal:  J Natl Cancer Inst       Date:  2000-04-05       Impact factor: 13.506

3.  Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

Authors:  K Obata; S J Morland; R H Watson; A Hitchcock; G Chenevix-Trench; E J Thomas; I G Campbell
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

4.  Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation.

Authors:  S Komiyama; D Aoki; E Tominaga; N Susumu; Y Udagawa; S Nozawa
Journal:  Gynecol Oncol       Date:  1999-03       Impact factor: 5.482

5.  Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary.

Authors:  So Yeon Park; Hee Sung Kim; Eun Kyung Hong; Woo Ho Kim
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

6.  Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.

Authors:  Julie A Irving; Lluis Catasús; Alberto Gallardo; Elena Bussaglia; Marisa Romero; Xavier Matias-Guiu; Jaime Prat
Journal:  Hum Pathol       Date:  2005-06       Impact factor: 3.466

7.  K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.

Authors:  M Cuatrecasas; A Villanueva; X Matias-Guiu; J Prat
Journal:  Cancer       Date:  1997-04-15       Impact factor: 6.860

8.  WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.

Authors:  M Al-Hussaini; A Stockman; H Foster; W G McCluggage
Journal:  Histopathology       Date:  2004-02       Impact factor: 5.087

9.  Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

Authors:  Viviane Hess; Roger A'Hern; Nazar Nasiri; D Michael King; Peter R Blake; Desmond P J Barton; John H Shepherd; T Ind; J Bridges; K Harrington; Stanley B Kaye; Martin E Gore
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

10.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Authors:  Joshua Z Press; Alessandro De Luca; Niki Boyd; Sean Young; Armelle Troussard; Yolanda Ridge; Pardeep Kaurah; Steve E Kalloger; Katherine A Blood; Margaret Smith; Paul T Spellman; Yuker Wang; Dianne M Miller; Doug Horsman; Malek Faham; C Blake Gilks; Joe Gray; David G Huntsman
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

View more
  2 in total

1.  Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.

Authors:  Mehmet Kanter; Gulay Turan; Ceyda Usta; Akin Usta; H Hasan Esen; Lema Tavlı; Cetin Celik; Yusuf Demirkol; Betül Kanter
Journal:  J Mol Histol       Date:  2016-01-27       Impact factor: 2.611

2.  The role of intratumoral lymphovascular density in distinguishing primary from secondary mucinous ovarian tumors.

Authors:  Bernardo Gomes de Lacerda Almeida; Carlos E Bacchi; Jesus P Carvalho; Cristiane R Ferreira; Filomena M Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2014-12       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.